Moderna's trading volume on February 5th was $480 million, ranking 334th among U.S. stocks on that day.

K-LinePoet · 2026-02-26T02:13:48+00:00

Moderna's trading volume on February 5, 2026, was $480 million, a 32.84% increase from the previous day. The stock price dropped 4.44% on that day, indicating recent poor performance, but it has gained 38.59% since the beginning of the year. The company's third-quarter report shows that revenue for fiscal year 2025 decreased by 44.23% year-over-year, but losses have narrowed. Moderna focuses on the development of mRNA drugs, dedicated to transforming human health.

K-LinePoet

2026-02-26 02:13:48

Abstract generation in progress

On February 5, 2026, biotechnology company Moderna (MRNA) had a trading volume of $480 million, ranking 334th among U.S. stocks that day. The trading volume increased by 32.84% compared to the previous day, with a total of 11.603 million shares traded.

On February 5, 2026, Moderna (MRNA) fell 4.44%, closing at $40.87. The stock has decreased 12.78% over the past 5 trading days, down 7.26% for the entire month of February, but has gained 38.59% since the beginning of the year, and increased 16.84% over the past 52 weeks.

If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to listings less than 1 month or fewer than 5 trading days).

Moderna (MRNA)	Trading Volume / USD	Change in Trading Volume from Previous Day	Shares Traded
February 5, 2026	$480 million	32.84%	11.603 million
February 4, 2026	$362 million	-9.66%	8.505 million
February 3, 2026	$400 million	-42.77%	9.368 million
February 2, 2026	$699 million	43.96%	16.1189 million
January 30, 2026	$486 million	-3.32%	10.9607 million

Moderna released its third-quarter 2025 financial report (cumulative) on November 6, 2025. From January 1 to September 30, 2025, revenue was $1.266 billion, a 44.23% decrease year-over-year, with a net loss of $1.996 billion, narrowing by 18.23% year-over-year.

Moderna, Inc. was incorporated on July 22, 2016, under Delaware law. The company is a leader in messenger RNA (mRNA) medicine. With over a decade of work at the intersection of science, technology, and health, it has developed drugs at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Its mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune conditions. Driven by a unique culture and a global team aligned with Moderna’s values and mindset, the company aims to responsibly change the future of human health by delivering the greatest possible impact through mRNA medicines.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.